Day one: The disruptor-in-chief at BridgeBio invites Brent Saunders onto the board
Now that Allergan has been swept up into AbbVie following their $63 billion buyout, it’s time for ex-CEO Brent Saunders to kickstart the next chapter of his career. And his new post as an independent board member at BridgeBio looks to be right up his alley.
BridgeBio, led by CEO Neil Kumar, has built up a hub-and-spoke operation involving a variety of subsidiaries on different development paths as the McKinsey vet looked to create a new kind of biopharma company, free of the usual corporate clutter that slows the giants down.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.